UPC_CoA_744/2025

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

BerufungenHauptberufungCourt of AppealGenericCase ClosedVergleich erfolgt: Nach PI

Übersicht Entscheidungen Dokumente Zeitverlauf

Parteien

Kläger

Samsung Bioepis NL B.V.

Vertreter: Peter Meyer (Simmons & Simmons LLP)

Beklagte

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Elena Hennecke (Freshfields Bruckhaus Deringer)

Richter

Rian KaldenLegally Qualified Judge and Standing Judge

Patente

EP 3 167 888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

Zurückgenommen

Eingereicht: 13. Aug. 2025

Erste Entscheidung: 18. Feb. 2026

Sprache: English

Vergleich erfolgt: Nach PI

The Court of Appeal permitted Samsung Bioepis NL B.V.'s withdrawal of two applications for leave to appeal cost decisions (UPC_CoA_744/2025 and UPC_CoA_750/2025) in proceedings relating to provisional measures dismissed for lack of urgency before the Hamburg Local Division. Alexion consented to the withdrawal and waived any costs claim. The proceedings were declared closed with no costs order.

Im UPC-Register öffnen